Table 1 Clinicopathological characteristics of 85 patients with metastatic renal cell carcinoma and tumor thrombus who received cytoreductive nephrectomy and thrombectomy
Age (years, range) | 58 (20–78) |
|---|---|
Gender | |
Male | 65 (76.5%) |
Female | 20 (23.5%) |
Weight (kg, range) | 63 (37–112) |
Height (cm, range) | 167 (149–183) |
Body mass index (kg/m2, range) | 22.8 (15.2–35.0) |
Symptom | |
No | 11 (12.9%) |
Local symptom | 39 (45.9%) |
Systemic symptom | 15 (17.6%) |
Both | 20 (23.5%) |
Mayo grade | |
0 | 12 (14.1%) |
1 | 27 (31.8%) |
2 | 31 (36.5%) |
3 | 7 (8.2%) |
4 | 8 (9.4%) |
Side | |
Left | 33 (38.8%) |
Right | 52 (61.2%) |
Tumor diameter (cm, range) | 9.4 (2.8–21.1) |
Major metastatic organs | |
Lung | 55 |
Bone | 23 |
Liver | 16 |
Adrenal | 13 |
Lymph node | 9 |
Single metastatic or not | |
Single site | 55 (64.7%) |
Multiple sites | 30(35.3%) |
ASA classification | |
1 | 8 (9.4%) |
2 | 60 (70.6%) |
3 | 15 (17.6%) |
4 | 2 (2.4%) |
Operation approach | |
Open | 42 (49.4%) |
Laparoscopy | 35 (41.2%) |
Robot-assisted laparoscopy | 8 (9.4%) |
Ipsilateral adrenalectomy | |
Yes | 52 (61.2%) |
No | 33 (38.8%) |
Partial resection of IVC | |
Yes | 14 (16.5%) |
No | 71 (83.5%) |
Lymph node dissection | |
Yes | 43 (50.6%) |
No | 42 (49.4%) |
Pathological type | |
Clear cell carcinoma | 61 (71.8%) |
Papillary cell carcinoma | 8 (9.4%) |
Other | 16 (18.8%) |
Nuclear grading | |
1 | 6 (7.1%) |
2 | 16 (18.8%) |
3 | 41 (48.2%) |
4 | 22 (25.9%) |
Sarcomatous degeneration | |
Yes | 16 (18.8%) |
No | 69 (81.2%) |
Perirenal fat infiltration | |
Yes | 34 (40.0%) |
No | 51 (60.0%) |
Preoperative Scr (ml/min/1.73 m2, range) | 91 (32–258) |
Postoperative Scr (ml/min/1.73 m2, range) | 95 (41–480) |
Operation time (min, range) | 289 (135–635) |
Intraoperative hemorrhage (ml, range) | 800 (10–6000) |
Complications | |
0 | 57 (67.1%) |
1 | 2 (2.4%) |
2 | 18 (21.2%) |
3 | 5 (5.9%) |
4 | 3 (3.5%) |
Serious complications | |
Yes | 8 (28.6%) |
No | 20 (71.4%) |
Postoperative systemic therapy | |
Targeted therapy | 67 (78.8%) |
Targeted therapy and immunotherapy | 18 (21.2%) |
IMDC score | |
0 | 42 (49.4%) |
1 | 29 (34.1%) |
2 | 14 (16.5%) |